on XSENSIO
Xsensio SA Secures $7M to Advance Biosensing Technology
Xsensio SA, a Swiss deep-tech company, has successfully closed a $7M oversubscribed Series A financing round. Leading the round was WI Harper, alongside Privilège Ventures and additional investors from the US, Europe, and Asia. The influx of capital is set to expedite the development and clinical validation of Xsensio's Lab-on-Skin© wearable biosensing platform.
This platform aims to provide continuous dynamic biochemical data, supporting clinical decision-making beyond hospital settings. Xsensio's CEO, Esmeralda Megally, emphasizes the potential impact of real-time biochemical monitoring on patient care, offering data previously unavailable at the point of care.
Additionally, a collaboration with Texas Instruments has been announced to enhance Xsensio's semiconductor technology capabilities, promising reliability and cost-effective deployment.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all XSENSIO news